BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
BridgeBio announced that it will present primary results from the Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia at the ICCBH 2026 conference. The company described the data to be shared as positive, marking a significant milestone for the global pivotal study. The late-breaking oral presentation is scheduled for June 28, led by Global Lead Investigator Dr.
Key figures
- Drug Name
- oral infigratinib
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.